Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia

14 augustus 2026 bijgewerkt door: The Methodist Hospital Research Institute

Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation

This study compares two FDA-approved surgical treatments for benign prostatic hyperplasia (BPH): Holmium Laser Enucleation of the Prostate (HoLEP) with MOSES 2.0 technology and Robotic Water Jet Ablation (RWJA) using the Hydros Robotic System. Men with BPH and prostate volumes between 50 and 180 mL will be randomly assigned to one of the two procedures. The study will measure changes in prostate volume, PSA, urinary flow, and bladder emptying at 12 months, along with safety, sexual function, continence, and healthcare utilization outcomes, which will be followed for up to 5 years after surgery.

Studie Overzicht

Gedetailleerde beschrijving

This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.

The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).

Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.

Studietype

Ingrijpend

Inschrijving (Geschat)

100

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  1. Male, age 50-80 years
  2. International Prostate Symptom Score (IPSS) ≥ 12
  3. Prostate size (TRUS): 50-180 mL
  4. Diagnosis of LUTS due to BPH
  5. Uroflow Qmax ≤ 15 mL/sec
  6. Mentally capable, able to comply with study procedures, written informed consent provided
  7. Able to follow study instructions and complete all required visits

Exclusion Criteria:

  1. BMI ≥ 42
  2. History of prostate cancer
  3. Suspected or history of bladder cancer
  4. Active or untreated bladder stones at screening
  5. Indwelling catheter for more than 3 months before baseline
  6. Active urinary tract infection
  7. History of urethral stricture or bladder neck stenosis
  8. Damage to the external urethral sphincter
  9. Previous prostate surgery or lower urinary tract surgery
  10. Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
  11. Contraindications to general and spinal anesthesia
  12. Any condition that could interfere with study participation or outcomes, per investigator judgment
  13. Lacks legal or mental capacity to consent
  14. Simultaneous participation in another therapeutic urological trial
  15. Known or persistent abuse of medication, drugs, or alcohol

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
Actieve vergelijker: RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Prostate Volume
Tijdsspanne: Baseline and 12 months post-intervention
Measured via transrectal ultrasound (TRUS); change from baseline.
Baseline and 12 months post-intervention
Change in Prostate-Specific Antigen (PSA)
Tijdsspanne: Baseline and 12 months post-intervention
Serum PSA level; change from baseline.
Baseline and 12 months post-intervention
Change in Urinary Flow Rate (Qmax)
Tijdsspanne: Baseline and 12 months post-intervention
Peak urinary flow rate via uroflowmetry; change from baseline.
Baseline and 12 months post-intervention
Change in Post-Void Residual Volume (PVR)
Tijdsspanne: Baseline and 12 months post-intervention
Bladder scan-measured PVR; change from baseline.
Baseline and 12 months post-intervention

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence and Severity of Adverse Events
Tijdsspanne: From patient hospital discharge through 3 and 12 months post-surgery
Adverse events graded by the Clavien-Dindo classification system.
From patient hospital discharge through 3 and 12 months post-surgery
Operative Time
Tijdsspanne: Day (duration) of surgical procedure
Total procedure time, start to finish.
Day (duration) of surgical procedure
Hemostasis Time
Tijdsspanne: Day (duration) of surgical procedure
Time required to achieve hemostasis intraoperatively.
Day (duration) of surgical procedure
Perioperative Change in Hemoglobin
Tijdsspanne: Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
Hemoglobin level change from baseline to immediate postoperative measurement.
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
Time to Catheter-Free Status
Tijdsspanne: From surgery day until catheter removal
Duration from end of surgery to catheter removal.
From surgery day until catheter removal
Length of Hospital Stay / Discharge Time
Tijdsspanne: Day of surgical procedure through hospital discharge
Time from surgery to hospital discharge.
Day of surgical procedure through hospital discharge
Change in IPSS/QoL Score
Tijdsspanne: Baseline, 3, 6, and 12 months post-surgery
International Prostate Symptom Score / Quality of Life index.
Baseline, 3, 6, and 12 months post-surgery
Change in SHIM Score
Tijdsspanne: Baseline, 3, 6, and 12 months post-surgery
Sexual Health Inventory for Men.
Baseline, 3, 6, and 12 months post-surgery
Change in MSHQ-EjD Score
Tijdsspanne: Baseline, 3, 6, and 12 months post-surgery
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
Baseline, 3, 6, and 12 months post-surgery
Change in Incontinence Outcomes
Tijdsspanne: Baseline, 3, 6, and 12 months post-surgery
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
Baseline, 3, 6, and 12 months post-surgery
Long-Term Durability of Functional Improvements
Tijdsspanne: 24, 36, 48, and 60 months post-intervention
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
24, 36, 48, and 60 months post-intervention
Post-Operative Medication Use
Tijdsspanne: Through 60 months post-intervention
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
Through 60 months post-intervention
Reintervention Rate
Tijdsspanne: Through 60 months post-intervention
Repeat procedures or additional therapies for BPH/LUTS.
Through 60 months post-intervention
Unplanned Healthcare Encounters
Tijdsspanne: Through 60 months post-intervention
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
Through 60 months post-intervention
Incidence of Urethral Stricture Requiring Intervention
Tijdsspanne: Through 60 months post-intervention
New urethral stricture or bladder neck stenosis requiring treatment.
Through 60 months post-intervention
Unanticipated Advanced Diagnostics
Tijdsspanne: Through 60 months post-intervention
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
Through 60 months post-intervention

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

3 augustus 2026

Primaire voltooiing (Geschat)

3 augustus 2029

Studie voltooiing (Geschat)

3 augustus 2033

Studieregistratiedata

Eerst ingediend

9 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 augustus 2026

Eerst geplaatst (Werkelijk)

19 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

14 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren